Skip to main content

Advertisement

Table 7 IMxRT series

From: Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer – a retrospective single center analysis

IMRT Series
Author Lee et al. Wolden et al. Kam et al. Kwong et al. Tham et al. Lee et al. Peponi et al. Own data
Year 2002 2006 2004 2006 2009 2009 2010 2012
Institution UCSF MSKCC PWH QMH NCC RTOG0225 USZ DKFZ
Region USA USA Hongkong Hongkong Singapore USA Switzerland Germany
n 67 74 63 50 195 68 39 49
f/u 31 35 29 25 27 31 30 48
Stage III/IV 70% 77% 57% 100% 56% 59% 85% 72%
sim. CHT 75% 93% 25% 68% 57% 83% 97% 100%
adj. CHT 75% 93% 0% 68% 35% 83% 97% 0%
TD 65-70 70 66 76 70 70 66-70 66-70,4
SD 2,12-2,25 2,34 o. CB 2 2,17 2,0-2,12 2,12 2,0-2,2 2,2
add. Boosts Br 40% CB 80% Br/3D 56% none Br 10% none none none
LC (year) 96% (4y) 91% (3y) 92% (3y) 96% (2y) 90% (3y) 93% (2y) 86% (3y) 90% (5y)
RC (year) 98% (4y) 93% (3y) 98% (3y) n.r. n.r. 91% (2y) 89% (3y) 98% (5y)
DC (year) 66% (4y) 78% (3y) 79% (3y) 94% (2y) 89% (3y) 85% (2y) 85% (3y) 86% (5y)
OS (year) 88% (4y) 83% (3y) 90% (3y) 92% (2y) 94% (3y) 80% (2y) 85% (3y) 79% (5y)
  1. n: number of patients, f/u: median follow up (months), sim.: simultaneous, adj.: adjuvant, CHT: chemotherapy, TD: total dose, SD: single dose, add.: additional, LC: local control, RC: regional control, DC: distant control, OS: overall survival, y: year, Br: Brachytherapy boost, CB: concomitant boost, 3D: 3d-confomal boost, nr : not reported, UCSF: University of California San Francisco [12], MSKCC: Memorial Sloan-Kettering Cancer Center [11], PWH: Prince of Wales Hospital [14], QMH: Queen Mary Hospital [13], NCC: National Cancer Center [21], RTOG: Radiation Therapy Oncology Group [22], USZ: Universitätsspital Zürich (University Hospital Zuerich) [23], DKFZ: Deutsches Krebsforschungszentrum (German Cancer Research Center).